Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity (RGDO). Early-onset severe obesity may result from genetic variants within the melanocortin-4 receptor (MC4R) pathway, a key hypothalamic pathway that regulates hunger, caloric intake, and energy expenditure, consequently affecting body weight. Rhythm is advancing a broad clinical development program across rare genetic diseases of obesity, including Bardet-Biedl syndrome (BBS), for the treatment of hunger and obesity due to genetic deficiencies associated with the MC4R pathway. In addition, Rhythm has created and is leveraging the largest known obesity DNA database of ~45,000 sequencing samples with the goal of improving the understanding, diagnosis, and care of patients with severe obesity due to certain genetic deficiencies. Rhythm’s Uncovering Rare Obesity® is a no-charge, comprehensive genetic testing program for RGDO.
Rhythm Pharmaceuticals
222 Berkeley St - 12th Fl
Boston, MA 02116
AAP Nat Con